Contact
searchSearch
HMP Global
Login

HER2 Videos

Sara Hurvitz, MD
Videos
Neoadjuvant and Adjuvant Treatment Options for Patients With HER2-Positive Breast Cancer
04/08/2025
Sara Hurvitz, MD
Sara Hurvitz, MD, discusses the neo/adjuvant options for patients with HER2-positive breast cancer.
Sara Hurvitz, MD, discusses the neo/adjuvant options for patients with HER2-positive breast cancer.
Sara Hurvitz, MD, discusses the...
04/08/2025
Oncology
Ciara O'Sullivan, MD
Videos
Trastuzumab Emtansine Plus Tucatinib for Patients With HER2-Positive Early Breast Cancer
02/04/2025
Ciara O'Sullivan, MD
Ciara O’Sullivan, MD, outlines the objectives of the CompassHER2 RD trial which aims to evaluate T-DM1 plus tucatinib in a cohort of patients with high-risk, HER2-positive early breast cancer.
Ciara O’Sullivan, MD, outlines the objectives of the CompassHER2 RD trial which aims to evaluate T-DM1 plus tucatinib in a cohort of patients with high-risk, HER2-positive early breast cancer.
Ciara O’Sullivan, MD, outlines...
02/04/2025
Oncology
Junjie Li, MD
Conference Coverage
Novel HER2-Directed Antibody Drug Conjugate in the Neoadjuvant Setting for Patients With HER2-Positive Breast Cancer
12/12/2024
Results from a phase 2 study found that SHR-A1822, a novel third generation HER2-directed antibody-drug conjugate, showed promise in the neoadjuvant setting for patients with HER2-positive breast cancer.
Results from a phase 2 study found that SHR-A1822, a novel third generation HER2-directed antibody-drug conjugate, showed promise in the neoadjuvant setting for patients with HER2-positive breast cancer.
Results from a phase 2 study...
12/12/2024
Oncology
Giuseppe Viale, MD
Conference Coverage
Assessing HER2-Low/-Ultralow Status Could Change Treatment Landscape for Patients With HR-Positive Metastatic Breast Cancer
10/29/2024
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses results from a comparison study which demonstrated that reassessing local and central immunostaining results can identify more patients with HER2-low or HER2-ultralow expression eligible for trastuzumab...
Giuseppe Viale, MD, discusses...
10/29/2024
Oncology
Oleg Gluz, MD
Videos
Neoadjuvant Endocrine Therapy vs De-Escalated Chemotherapy for HR-Positive, HER2-Positive Early Breast Cancer
09/15/2024
Oleg Gluz, MD
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...
Oleg Gluz, MD, discusses results from the phase 2 WSG-TP-II trial which investigated survival outcomes with neoadjuvant endocrine therapy plus trastuzumab and pertuzumab vs de-escalated chemotherapy plus trastuzumab and pertuzumab in...
Oleg Gluz, MD, discusses results...
09/15/2024
Oncology
Erika Hamilton, MD, Sarah Cannon Research Institute
Videos
Trastuzumab Deruxtecan Maintains Superiority Over Trastuzumab Emtansine Among Patients With HER2-Positive Metastatic Breast Cancer
06/20/2024
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the long-term analysis from the phase 3 DESTINY-Breast03 trial which reinforced the superiority of trastuzumab deruxtecan over trastuzumab emtansine for patients with HER2-positive metastatic breast cancer...
Erika Hamilton, MD discusses the...
06/20/2024
Oncology
Sara Hurvitz, MD, Fred Hutchinson Cancer Center
Videos
Tucatinib Plus Trastuzumab Emtansine Improved Progression-Free Survival Among Patients With HER2-Positive Metastatic Breast Cancer
12/06/2023
Sara Hurvitz, MD
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results from the HER2CLIMB-02 trial evaluating tucatinib plus trastuzumab emtansine among patients with previously-treated HER2-positive metastatic breast cancer.
Sara Hurvitz, MD, shares results...
12/06/2023
Oncology
Clinton Yam, MD, MD Anderson Cancer Center, Houston, TX
Videos
Characteristics of HER2-Low vs HER2-Zero Early-Stage Triple-Negative Breast Cancer
03/06/2023
At the 2022 San Antonio Breast Cancer Symposium, Clinton Yam, MD, discussed the clinical and molecular characteristics of HER2-low early-stage triple-negative breast cancer compared to HER2-zero early-stage triple-negative breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Clinton Yam, MD, discussed the clinical and molecular characteristics of HER2-low early-stage triple-negative breast cancer compared to HER2-zero early-stage triple-negative breast cancer.
At the 2022 San Antonio Breast...
03/06/2023
Oncology
Aditya Bardia, MD, Massachusetts General Hospital, Boston, MA
Videos
Neoadjuvant Trastuzumab Deruxtecan for HER2-Low, HR-Positive Breast Cancer
02/02/2023
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of neoadjuvant trastuzumab deruxtecan for patients with HER2 low, HR-positive early-stage breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Aditya Bardia, MD, discusses the efficacy of neoadjuvant trastuzumab deruxtecan for patients with HER2 low, HR-positive early-stage breast cancer.
At the 2022 San Antonio Breast...
02/02/2023
Oncology
Sara Hurvitz, MD, David Geffen School of Medicine
Videos
Trastuzumab Deruxtecan for HR-Positive, HER2-Low, Early-Stage Breast Cancer
12/22/2022
At the 2022 San Antonio Breast Cancer Symposium, Sara Hurvitz, MD, presents preliminary results from the TRIO-US B-12 TALENT trial, investigating trastuzumab deruxtecan for patients with HR-positive, HER2-low, early-stage breast cancer.
At the 2022 San Antonio Breast Cancer Symposium, Sara Hurvitz, MD, presents preliminary results from the TRIO-US B-12 TALENT trial, investigating trastuzumab deruxtecan for patients with HR-positive, HER2-low, early-stage breast cancer.
At the 2022 San Antonio Breast...
12/22/2022
Oncology

Recent News

News
Tegafur-Uracil Maintenance Did Not Improve Survival for Patients With Locally Advanced Cervical Cancer
04/15/2025
Stephanie Holland
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the phase 3 GOTIC-002 trial, low-dose tegafur-uracil maintenance therapy did not improve survival among patients with locally advanced cervical cancer.
According to results from the...
04/15/2025
Oncology
News
First-Line Durvalumab Plus Platinum-Etoposide for Patients With Extensive-Stage Small Cell Lung Cancer
04/14/2025
Stephanie Holland
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and safety results from the phase 3b LUMINANCE trial, first-line durvalumab plus platinum-etoposide demonstrated promise among patients with extensive-stage small cell lung cancer.
According to final efficacy and...
04/14/2025
Oncology
News
Tilsotolimod Plus Ipilimumab Fails to Significantly Improve Outcomes for Patients With Advanced Refractory Melanoma
04/11/2025
Stephanie Holland
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
According to results from the phase 3 ILLUMINATE-301 study, the addition of tilsotolimod to ipilimumab did not significantly improve outcomes among patients with advanced refractory melanoma.
According to results from the...
04/11/2025
Oncology
News
Cytokine and Chemokines as Predictive Biomarkers of CAR-T Therapy Outcomes in Large B-Cell Lymphoma
04/11/2025
Emily Estrada
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine levels may be used as predictive biomarkers of CAR-T therapy response and toxicity among patients with large B-cell lymphoma.
Plasma cytokines and chemokine...
04/11/2025
Oncology
News
The Potential of Targeting NRG1 for Esophageal Squamous Cell Carcinoma
04/10/2025
Allison Casey
Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.
Targeting NRG1 may present a potential treatment strategy for esophageal squamous cell carcinoma.
Targeting NRG1 may present a...
04/10/2025
Oncology
News
First-Line Cemiplimab Demonstrates Long-Term Efficacy Among Patients With Advanced Non-Small Cell Lung Cancer With PD-L1 ≥ 50%
04/09/2025
Stephanie Holland
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial, first-line cemiplimab demonstrated continued efficacy compared to chemotherapy among patients with advanced non-small cell lung cancer with PD-L1 expression ≥ 50%.
According to 5-year follow-up...
04/09/2025
Oncology
News
Odronextamab Demonstrates Durability and Safety for Relapsed/Refractory DLBCL
04/09/2025
Emily Estrada
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for relapsed/refractory diffuse large B-cell lymphoma with odronextamab demonstrated a manageable safety profile and durable responses among patients previously treated with 2 lines of therapy.
Treatment for...
04/09/2025
Oncology
News
Long-Term Real-World Efficacy of CPX-351 Therapy for Patients With High-Risk AML
04/09/2025
Emily Estrada
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world analysis, CPX-351 induction therapy was significantly associated with achievement of measurable residual disease status, which was correlated with improved overall survival among patients with high-risk AML.
In a long-term, real-world...
04/09/2025
Oncology
FDA Approval
FDA Approves Nivolumab Plus Ipilimumab for Unresectable/Metastatic Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer
04/08/2025
Stephanie Holland
Based on results from the CHECKMATE-8HW trial, the FDA has approved nivolumab plus ipilimumab for patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal...
Based on results from the CHECKMATE-8HW trial, the FDA has approved nivolumab plus ipilimumab for patients 12 years of age and older with unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal...
Based on results from the...
04/08/2025
Oncology
News
First-Line Pembrolizumab With or Without Chemotherapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
04/08/2025
Stephanie Holland
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up results from the phase 3 KEYNOTE-048 study, first-line pembrolizumab with or without chemotherapy demonstrated long-term survival benefit among patients with recurrent or metastatic head and neck squamous cell...
According to long-term follow up...
04/08/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use